By Clinical Research Team  

April 25, 2024 | PathAI announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology labs accelerate the adoption of AI and digital pathology; Clinical ink has launched GlucoseReady, a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials; New England Biolabs has released its Monarch Mag Viral DNA/RNA Extraction Kit, which enhances recovery of low amounts of viral nucleic acid to enable highly sensitive detection; more. 

PathAI announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology (AP) labs accelerate the adoption of AI and digital pathology. The partnership will involve the integration of PathAI’s AISight solution with Google Cloud's infrastructure and AI capabilities, providing accelerated adoption of precision medicine solutions and customized solutions and tailored AI models. Press release. 

Clinical ink has launched GlucoseReady, a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools includes disease specific electronic clinical outcomes (eCOA) assessments, behavioral assessment by the SPUR tool, lifestyle standardization, blood (BGM), and continuous glucose monitoring (CGM), digital weight scale and actigraphy. Unique endpoint features include the ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance. Novel compliance features include prediction, tracking, and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance. Press release. 

CureVac and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need. Press release. 

New England Biolabs has released its Monarch Mag Viral DNA/RNA Extraction Kit. This extraction kit enhances recovery of low amounts of viral nucleic acid to enable highly sensitive detection. The kit uses a magnetic bead-based process to extract viral RNA and DNA reproducibly and efficiently, while enabling scale up for high-throughput automation. The kit is compatible with the most common sample types for extracting viral nucleic acids, including saliva, respiratory swab samples and, following an enrichment step, wastewater samples. Press release. 

Qinecsa Solutions announced its acquisition of Insife ApS (Insife), a well-established Danish-based software, technology, and consultancy firm specializing in developing revolutionary pharmacovigilance platforms. This acquisition is in alignment with Qinecsa’s vision, playing a crucial role in the company's pursuit to become the leading provider of digital pharmacovigilance solutions. Press release. 

Nucleai announced a strategic collaboration with GoPath Diagnostics. This collaboration aims to offer AI-powered digital pathology solutions for clinical trials and diagnostics and foster innovative research by combining Nucleai’s expertise in spatial biology and AI with GoPath’s access to multi-modal real-world data, world-class lab services, and cutting-edge molecular capabilities. The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists, Clinical Laboratory Improvement Amendments, Clinical Laboratory Evaluation Program, Good Clinical Practice, and Good Clinical Laboratory Practice. This will support clinicians and biopharma partners throughout all stages of oncology and immunology drug development. Press release. 

Andaman7 has launched an update with advanced artificial intelligence (AI) capabilities. Version 5 of the app offers patients deeper insights into their own data, allowing researchers to leverage increased patient engagement for easier, faster, and better-quality studies and post market research. Andaman7 v5 offers patients an enhanced understanding of their health record documents through three new AI tools: simplification—Andaman7 AI streamlines complex medical information, converting medical jargon into text which is easier for patients to understand; summarization—an AI-powered summarization extracts key insights allowing patients to quickly grasp the content of lengthy reports; and translation—a translation tool ensures health information is always accessible and understood, regardless of the document’s original language or the reader’s language. Press release. 

myTomorrows announced a new partnership with brainstrust. Under the partnership, people with brain tumors will be equipped with the means to bolster their knowledge of relevant treatment options, potentially extending to participation in clinical trials and access to pre-approval drugs. Moreover, the partnership provides a new layer of support to clinicians in their efforts to recruit patients to relevant clinical trials. Press release. 

PreciseDx announced a sponsored research collaboration with UCLA's Department of Pathology and Laboratory Medicine in Los Angeles to evaluate PreciseBreast's ability to accurately assess risk of recurrence for patients with triple-negative breast cancer (TNBC). TNBC constitutes only 10-20% of all breast cancer cases yet continues to demand significant clinical interest due to its limited response to conventional treatments, the association with younger women, BRCA1/2 mutations, ethnic/racial disparities, and its highly aggressive characteristics. The current study will expand on the previous subgroup analysis of TNBC patients from the PreciseBreast-Mount Sinai Hospital, NY, validation study with a large, well-annotated outcome-based TNBC cohort from the UCLA Health System. Press release.